Table 1.
Group | 0 week | 4 weeks | 8 weeks | 12 weeks |
---|---|---|---|---|
Control | 212.8 ± 10.5 | 332.7 ± 12.7 | 438.0 ± 8.4 | 514.7 ± 7.2 |
DN | 212.0 ± 7.1 | 224.3 ± 11.4a | 242.2 ± 9.0a | 261.5 ± 3.8a |
DN + leflunomide | 215.3 ± 9.7 | 256.0 ± 7.2a,b | 271.5 ± 5.4a,b | 297.3 ± 13.1a,b |
DN + benazepril | 222.7 ± 6.2 | 255.2 ± 14.0a,b | 275.3 ± 10.3a,b | 300.2 ± 15.1a,b |
DN + leflunomide and benazepril | 217.3 ± 6.3 | 272.0 ± 9.0a,b,c,d | 304.2 ± 5.6a,b,c,d | 334.3 ± 13.0a,b,c,d |
p < .05, compared with the control group.
P < .05, compared with the DN group.
p < .05, compared with the DN + leflunomide group.
p < .05, compared with the DN + benazepril group. 0 week means the time for successful establishment of the DN model.